13 recruiting, 11 unknown, 9 not yet recruiting, 3 active not recruiting. 14 Phase 2, 7 Not applicable, 7 Phase 3, 2 Phase 1.
Follow Adjuvant Therapy: new trials by email Literature Review of Adjuvant Therapy trials Research Report on Adjuvant Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast Cancer CDK4/6 inhibitor, Endocrine Therapy (Optional) - Breast Cancer, Adjuvant Therapy | Phase 2 | Not yet recruiting | Fudan University | 494 | 2026-09-15 | 2026-09-17 |
| A Non-interventional, Real-world Study on the Adjuvant Treatment of Chinese EGFR-positive Stage IA NSCLC Patients With High-risk Factors Using Third-generation EGFR-TKIs. Third-generation EGFR-TKI - Non-Small Cell Lung Cancer, Adjuvant Therapy | Not yet recruiting | First Affiliated Hospital of Guangxi Medical University | 500 | 2026-09-01 | 2026-07-07 | |
| Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma Becotatug Vedotin - Nasopharyngeal Carcinoma (NPC), Locoregionally Advanced Nasopharyngeal Carcinoma | Phase 2 | Not yet recruiting | Kai Hu | 140 | 2026-09-01 | 2026-06-09 |
| A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer. Aipaluoli-tovorilimab plus AC-T chemotherapy as postoperative adjuvant therapy - TNBC, Adjuvant Therapy | Not applicable | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 59 | 2026-06-05 | 2026-06-03 |
| A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer Camrelizumab, famotinib - Cervical Cancer, Radical Surgery | Not applicable | Not yet recruiting | Jin LI | 30 | 2026-04-01 | 2026-03-12 |
| An Antibody-armored Dendritic Cell in Patients With Solid Tumors Armored Dendritic Cell Injection - Solid Cancers, Adjuvant Therapy | Phase 1 | Recruiting | Shanghai Cell Therapy Group Co.,Ltd | 8 | 2026-02-05 | 2026-03-18 |
| Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma PD-1 Inhibitors - HCC, Adjuvant Therapy | Not yet recruiting | Tongji Hospital | 300 | 2026-01-31 | 2026-01-30 | |
| Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors: Adjuvant Therapy, CDK4/6 Inhibitor | Recruiting | European Institute of Oncology | 750 | 2025-09-29 | 2026-05-29 | |
| Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients Dalpiciclib, Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane) - Early Breast Cancer, Adjuvant Therapy | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 200 | 2025-09-01 | 2025-08-03 |
| Pucotenlimab Combined With Chemotherapy as Perioperative Treatment for Locally Advanced Gastroesophageal Junction Carcinoma Neoadjuvant chemo-immunotherapy - Gastroesophageal Junction, Gastric / Gastroesophageal Junction Adenocarcinoma | Not applicable | Not yet recruiting | Tang-Du Hospital | 30 | 2025-08-01 | 2025-07-29 |
| Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer Chemotherapy, CDK4/6 Inhibitor, Endocrine therapy - Breast Cancer, Adjuvant Therapy | Phase 3 | Not yet recruiting | Fudan University | 1244 | 2025-06-15 | 2025-06-05 |
| CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS) Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Standard endocrine therapy combined with CDK4/6 Inhibitor - Breast Cancer, Adjuvant Therapy | Phase 3 | Recruiting | Fudan University | 1903 | 2025-06-15 | 2026-01-21 |
| Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma postoperative adjuvant therapy - Sarcomatoid Carcinoma, Liver Cancer | Recruiting | West China Hospital | 50 | 2025-04-05 | 2025-04-30 | |
| Reduce Sedentary Behavior During Cancer Treatment - the RedSedCan Study Digital self-management program - Breast Cancer, Colorectal Cancer (CRC) | Not applicable | Recruiting | Mälardalen University | 210 | 2025-03-01 | 2026-10-01 |
| Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC Sintilimab - Non-Small Cell Lung Cancer, Adjuvant Therapy | Phase 2 | Recruiting | Sichuan University | 100 | 2025-01-10 | 2026-08-05 |
| MRD in PAAD Adjuvant Therapy Three-drug chemotherapy group, two-drug chemotherapy group - The Role of Molecular Residual Disease in the Treatment Strategy and Prognosis Prediction of Pancreatic Cancer Patients Undergoing Adjuvant Therapy, Molecular Residual Disease | Not applicable | Active not recruiting | Peking Union Medical College Hospital | 60 | 2024-10-15 | 2025-03-10 |
| Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Hormone Therapy in Patients with RH+ ,HER2-nonoveramplified Breast Cancer, Real-life Data (MONARCHE29) Brest Cancer, Abemaciclib | Unknown | University Hospital, Brest | 30 | 2024-09-26 | 2024-10-01 | |
| Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma Donafenib - Hepatocellular Carcinoma, Adjuvant Therapy | Not applicable | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 204 | 2024-08-28 | 2024-09-03 |
| The Significance and Indications of Surgery for Synchronous Liver Metastatic Pancreatic Cancer Pancreatic Cancer, Liver Metastases | Unknown | China-Japan Friendship Hospital | 50 | 2024-08-23 | 2025-04-16 | |
| Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer Irinotecan liposome injection - Pancreatic Cancer, Adjuvant Therapy | Not applicable | Recruiting | Kuirong Jiang | 53 | 2024-04-08 | 2024-04-11 |
Showing 20 of 40. Sign in to see all of them.
Breast Neoplasms (8) · Carcinoma, Hepatocellular (4) · Carcinoma, Non-Small-Cell Lung (4) · Pancreatic Neoplasms (4) · Recurrence (4) · Colonic Neoplasms (3) · Stomach Neoplasms (2) · Adenocarcinoma (1) · Carcinoma (1) · Colorectal Neoplasms (1) · Disease (1) · Endometrial Stromal Tumors (1) · Esophageal Squamous Cell Carcinoma (1) · Liver Neoplasms (1) · Melanoma (1)
Neoplasms (31) · Neoplasms by Site (30) · Digestive System Diseases (16) · Digestive System Neoplasms (16) · Neoplasms by Histologic Type (10) · Skin Diseases (9) · Skin and Connective Tissue Diseases (9) · Breast Diseases (8) · Neoplasms, Glandular and Epithelial (8) · Carcinoma (7) · Gastrointestinal Diseases (7) · Gastrointestinal Neoplasms (7) · Liver Diseases (5) · Adenocarcinoma (4) · Bronchial Neoplasms (4)
sintilimab (4) · Drug Therapy (3) · Anastrozole (2) · Letrozole (2) · Oxaliplatin (2) · Tamoxifen (2) · Trastuzumab (2) · exemestane (2) · tislelizumab (2) · Albumin-Bound Paclitaxel (1) · Aspirin (1) · Bevacizumab (1) · Carboplatin (1) · Chemoradiotherapy (1) · Docetaxel (1)
Fudan University (5) · Sichuan University (3) · Lei Li (2) · Second Affiliated Hospital, Zhejiang University, School of Medicine (2) · Anhui Provincial Hospital (1) · Betta Pharmaceuticals Co., Ltd. (1) · Chen Xiaoping (1) · China-Japan Friendship Hospital (1) · European Institute of Oncology (1) · First Affiliated Hospital of Guangxi Medical University (1) · Fujian Cancer Hospital (1) · Fujian Medical University Union Hospital (1) · Guo Xufeng (1) · Jin LI (1) · Kai Hu (1)
China (28) · France (2) · Italy (2) · Sweden (2) · Belgium (1) · Croatia (1) · Netherlands (1) · Spain (1)
Lei Li, M.D. (2) · Changqing Pan (1) · Changzhen Shang, MD (1) · G.J. Liefers, MD PhD (1) · Hans von der Maase, MD PhD (1) · Jeanne Suissa (1) · Johan Hansson, MD,PhD (1) · KuiRong Jiang, archiater (1) · Lars Bastholt, MD,PhD (1) · Lianxin Liu, Ph.D. (1) · Meijuan Huang, MD (1) · Micaela Hernberg, MD, PhD (1) · Nadia Bianco, MD (1)
PMID 21256809, PMID 24419108, PMID 25832001, PMID 26028255, PMID 28241187, PMID 29727332, PMID 31513484, PMID 32251400, PMID 34160577, PMID 35764956, PMID 41160302